WilmerHale Reps Eleven Biotherapeutics in Acquisition of Viventia Bio

Download IconDownload Print IconPrint

WilmerHale Reps Eleven Biotherapeutics in Acquisition of Viventia Bio

Firm News

Related Solutions

WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
A deep and diverse practice focused on maximizing tax efficiencies and minimizing tax risks for clients nationally and internationally.
With a team of lawyers recognized nationally as leading practitioners in the field, we regularly advise public and private companies, their shareholders and their key employees on tax aspects of mergers, acquisitions, dispositions and joint ventures. Clients rely on our advice to maximize their tax efficiencies and minimize their tax risks. Our clients include businesses from a wide range of sectors: technology, life sciences, publishing, telecommunications, aviation and defense, venture capital and private equity. We develop tax-efficient structures that help clients achieve business objectives and negotiate appropriate contractual protections against the assumption of unwanted tax risks.
Lawyers with deep and broad experience counseling clients in every industry on the design, implementation, and interpretation of executive compensation arrangements and on general compensation and benefits issues.

Eleven Biotherapeutics, Inc. and Viventia Bio Inc. announced that the two companies and the shareholders of Viventia entered into a definitive share purchase agreement under which Eleven Biotherapeutics agreed to, and simultaneously completed, the acquisition of Viventia.

The acquisition creates a NASDAQ-listed company focused on the development of novel therapies based upon antibody fragments genetically fused to cytotoxic proteins, or targeted protein therapeutics, as new treatments in areas of oncology with significant unmet need.

The WilmerHale representation was led by Partners Brian Johnson and Hal Leibowitz (M&A). The Corporate team included Partner Belinda Juran, Counsel Chris Barnstable-Brown, Senior Associate Ryan Mitteness, and Associates Claire Sarno, Colin Beauvais and John Wagner. Tax, Executive Compensation and Employee Benefits advice was provided by Partners Bill Caporizzo, Amy Null, Laura Schneider and Kimberly Wethly, and Counsel Meghan Walsh. 

Read the press release for more information.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel